Apr 27, 2016

Posted by in Biotech Stocks | 0 Comments

Trader’s Round Up: Oncothyreon Inc (NASDAQ:ONTY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Anavex Life Sciences Corp (NASDAQ:AVXL)

Trader’s Round Up: Oncothyreon Inc (NASDAQ:ONTY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Anavex Life Sciences Corp (NASDAQ:AVXL)

Oncothyreon Inc (NASDAQ:ONTY) plunged -2.96% and ended at $1.31. The total traded volume was 1.73 million shares and market capitalization arrived at $138.79 million. The stock has a 52-week high price of $4.69 and its 52-week low was recorded at $0.90, while during last trade its minimum price was $1.21 and it gained the highest price of $1.43.

Oncothyreon Inc (NASDAQ:ONTY) on March 29, 2016 announced the appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors.

Myers, 49, brings more than 20 years of industry expertise, including significant management, commercialization and business development experience in multinational pharmaceutical companies. Myers most recently served as Chief Executive Officer and President for Aerocrine AB, a life sciences company based in Stockholm, Sweden and Morrisville, NC. Aerocrine was acquired by Circassia Pharmaceuticals, a UK-based immunotherapy company, in July of 2015.  Myers also served as an independent Director for Orexo, AB, a pharmaceutical company and is currently an industry advisor to EQT, a large Scandinavian investment fund.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported the decrease of -1.77% to close at $84.14 with the overall traded volume of 1.69 million shares. Its market capitalization on last close reached to $20.46 billion. Its beta value stands at 0.57 times. The company has the total of 246.39 million outstanding shares. Its intraday-low price was $83.29 and its hit its day’s highest price at $87.45.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on April 15, 2016 announced that it will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET.

The conference call will be webcast live and a link to the webcast can be accessed through Vertex’s website at www.vrtx.com in the “Investors” section under “Events and Presentations.”

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Anavex Life Sciences Corp (NASDAQ:AVXL) moved down -2.64% to settle at $5.90. Its total traded volume during last trading session was 1.67 million shares. The overall market worth of this company is about $216.32 million. The 52 week range of the stock remained $1.08 – $14.84, while its day’s lowest price was $5.70 and its hit its day’s highest price at $6.49. The beta of this stock currently stands at 0.18.

Anavex Life Sciences Corp (NASDAQ:AVXL) on April 8, 2016 announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).

Frontotemporal dementia describes a clinical syndrome associated with progressive shrinking of the frontal and temporal anterior lobes of the brain.  It causes a decline in language and/or behavioral changes, which include inappropriate social conduct, lack of empathy, blunted emotions or agitation, neglect of personal hygiene and a decrease in energy and motivation.  To date, no treatment has been shown to slow its progression and the prognosis for people with FTD is poor.  FTD afflicts an estimated 50,000 to 60,000 patients in the United States and represents an estimated 10 to 20 percent of all dementia cases.

FDA Orphan Drug Designation is evaluated for drugs from all classes that are intended for the treatment of rare diseases, defined as diseases affecting fewer than 200,000 people in the United States.  The designation provides sponsors with development and commercial incentives, including seven years of market exclusivity in the U.S., prioritized consultation by FDA on clinical studies and certain exemptions from or reductions in regulatory fees.


Comments are closed.